Recon Top Stories DePuy Synthes Launches VELYS™ Hip Navigation with AI to Support Intraoperative Consistency and Efficiency in Total Hip Arthroplasty byJosh SandbergJune 10, 2026
Financial Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025 byTim AllenOctober 14, 2025
Financial Recon J&J to spin off orthopedics business, sees 2026 sales growth of over 5% byWill SandbergOctober 14, 2025
Financial Medtech M&A has remained slow this year. But 2 execs are ready to make a deal byJosh SandbergOctober 8, 2025
Recon USOP Names Johnson & Johnson Its Official Vendor for Total Joint Products byJosh SandbergOctober 2, 2025
Regulatory U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor byNoah SimmonsSeptember 29, 2025
Extremities Top Stories DePuy Synthes Acquires CrossRoads® Extremity Systems to Further Strengthen Elective Foot & Ankle Portfolio byJosh SandbergFebruary 10, 2022
Extremities DePuy Synthes Launches 2.7 mm Variable Angle Locking Compression Plate Clavicle System Designed to Accommodate Different Shapes and Sizes of the Collarbone byJosh SandbergJune 9, 2021
Spine DePuy Synthes Announces Exclusive Expandable Cage Distribution Agreement with Expanding Innovations Inc. byJosh SandbergFebruary 2, 2021
